<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03755102</url>
  </required_header>
  <id_info>
    <org_study_id>18-341</org_study_id>
    <nct_id>NCT03755102</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.</brief_title>
  <official_title>A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progressionon Osimertinib.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether dacomitinib after osimertinib is effective in
      participants with metastatic EGR-mutant lung cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Overall response rate (partial and complete responses) of dacomitinib in participants with EGFR-mutant lung cancers and disease progression on osimertinib</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>EGFR Gene Mutation</condition>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Metastatic EGFR-Mutant Lung Cancer with evidence of C797S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic EGFR-Mutant Lung Cancer with no evidence of C797S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacomitinib</intervention_name>
    <description>Dacomitinib (45mg) administered as a once daily dose (irrespective of food intake). Concomitant use of proton pump inhibitors with dacomitinib should be avoided if possible, and if necessary, dosing timing should be spaced apart (morning and evening).</description>
    <arm_group_label>Metastatic EGFR-Mutant Lung Cancer with evidence of C797S</arm_group_label>
    <arm_group_label>Metastatic EGFR-Mutant Lung Cancer with no evidence of C797S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Advanced biopsy-proven metastatic non-small cell lung cancer

          -  Somatic activating mutation in EGFR in a tumor biopsy

          -  Prior treatment with osimertinib with response followed by disease progression

          -  No prior first or second generation EGFR inhibitor treatment (gefitinib, afatinib,
             erlotinib)

          -  Archival tissue available from a tumor biopsy done after disease progression on
             osimertinib or willing to undergo a tumor biopsy after disease progression on
             osimertinib prior to study initiation

          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated

          -  Karnofsky performance status (KPS) &gt;/= 70%

          -  Age &gt;/= 18 years old

          -  Ability to swallow oral medication

          -  Adequate organ function

               -  AST, ALT &lt;/= 3 x ULN

               -  Total bilirubin &lt;/= 1.5x ULN

               -  Creatinine &lt;/= 1.5x ULN OR calculated creatinine clearance &gt;/= 60ml/min

               -  Absolute neutrophil count (ANC) &gt;/= 1000 cells/mm3

               -  Hemoglobin&gt;/=8.0 g/dL

               -  Platelets &gt;/=75,000/mm3

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Any radiotherapy within 1 week of starting treatment on protocol.

          -  Any major surgery within 1 weeks of starting treatment on protocol.

          -  Any evidence of active clinically significant interstitial lung disease

          -  Continue to have unresolved &gt; grade 1 toxicity from any previous treatment Treatment

          -  Patients with a known mechanism of resistance to osimertinib that will clearly not
             respond to dacomitinib therapy (i.e. known MET amplification, ALK fusion, RET fusion).

          -  Symptomatic brain metastases or leptomeningeal disease requiring escalating doses of
             steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Yu, MD</last_name>
    <phone>646-888-4274</phone>
    <email>YuH@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Kris, MD</last_name>
    <phone>646-888-4205</phone>
    <email>krism@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Tu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Yu, MD</last_name>
      <phone>646-888-4274</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR C797S</keyword>
  <keyword>EGFR mutant lung cancer</keyword>
  <keyword>dacomitinib</keyword>
  <keyword>osimertinib</keyword>
  <keyword>18-341</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

